All In Biotech

Drug Trial Radar · NCT03484702

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

113

Actual

Start

Jun 5, 2018

Primary completion

Dec 15, 2023

Study completion Dec 15, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • JCAR017Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3Time frame: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)
  2. Overall Response Rate (ORR) Per Investigator in Cohort 4Time frame: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)
  3. Overall Response Rate (ORR) Per Investigator in Cohort 5Time frame: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)
  4. Number of Participants With Adverse Events in Cohort 7Time frame: From leukapheresis to end of study (up to approximately 63 months)
  5. Number of Participants With Serious Adverse Events (SAEs) in Cohort 7Time frame: From leukapheresis to end of study (up to approximately 63 months)
  6. Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7Time frame: At Baseline and Day 29 after JCAR017 infusion
  7. Number of Participants With Increase From Baseline in Select Serum Chemistry Parameters - Cohort 7Time frame: At Baseline and Day 29 after JCAR017 infusion

Locations

20 sites in 11 countries. Site status is shown where the registry gives one.

  • Local Institution - 101

    Vienna, Austria

  • Local Institution - 351

    Ghent, Belgium

  • Local Institution - 551

    Helsinki, Finland

  • Local Institution - 202

    Lille, France

  • Local Institution - 203

    Paris, France

  • Local Institution - 201

    Pierre-Bénite, France

  • Local Institution - 151

    Cologne, Germany

  • Local Institution - 152

    Dresden, Germany

  • Local Institution - 155

    Heidelberg, Germany

  • Local Institution - 154

    München, Germany

  • Local Institution - 153

    Ulm, Germany

  • Local Institution - 402

    Milan, Italy

  • Local Institution - 401

    Torino, Italy

  • Local Institution - 601

    Chuo-ku, Tokyo, Japan

  • Local Institution - 602

    Minato-ku, Tokyo, Japan

  • Local Institution - 301

    Rotterdam, Netherlands

  • Local Institution - 451

    Barcelona, Spain

  • Local Institution - 251

    Bern, Switzerland

  • Local Institution - 501

    London, United Kingdom

  • Local Institution - 502

    Manchester, Lancashire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.